Biocon to acquire debentures of Biocon Biologics from Goldman Sachs for $198.5 mn

Under the agreement, the company will acquire 1,047 OCDs from Goldman Sachs India Alternative Investment Trust AIF Scheme 2 and 78 OCDs from Goldman Sachs India AIF Scheme-1